Endoglin/CD105 Antibody (166707) [Unconjugated]

U937 human histiocytic lymphoma cell line was stained with Mouse Anti-Human Endoglin/CD105 Monoclonal Antibody (Catalog # MAB10971, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow, CyTOF-ready
• Clone: 166707
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

Endoglin/CD105 Antibody (166707) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Endoglin/CD105
  Glu26-Gly586
  Accession # Q5T9B9
• Specificity: Detects human Endoglin/CD105.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: ENG

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/10^6 cells
  • CyTOF-ready
• Control:

  Endoglin/CD105 Knockout HeLa Cell Lysate

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Endoglin/CD105 Antibody (166707) [Unconjugated]

• CD105 antigen
• CD105
• Endoglin
• ENDOsler-Rendu-Weber syndrome 1
• ENG
• HHT1FLJ41744
• ORW
• ORW1

Background

Endoglin (CD105) is a 90 kDa type I transmembrane glycoprotein of the zona pellucida (ZP) family of proteins (1‑3). Endoglin and betaglycan/T beta RIII are type III receptors for TGF beta superfamily ligands, sharing 71% aa identity in the transmembrane (TM) and cytoplasmic domains. Endoglin is highly expressed on proliferating vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta, with lower amounts on hematopoietic, mesenchymal and neural crest stem cells, activated monocytes, and lymphoid and myeloid leukemic cells (2‑5). Human Endoglin cDNA encodes 658 amino acids (aa) including a 25 aa signal sequence, a 561 aa extracellular domain (ECD) with an orphan domain and a two-part ZP domain, a TM domain and a 47 aa cytoplasmic domain (1‑3). An isoform with a 14 aa cytoplasmic domain (S-endoglin) can oppose effects of long (L) Endoglin (6, 7). The human Endoglin ECD shares 65-72% aa identity with mouse, rat, bovine, porcine and canine Endoglin. Endoglin homodimers interact with TGF-beta 1 and TGF-beta 3 (but not TGF-beta 2), but only after binding T beta RII (8). Similarly, they interact with activin-A and BMP-7 via activin type IIA or B receptors, and with BMP-2 via BMPR-1A/ALK-3 or BMPR-1B/ALK-6 (9). BMP-9, however, is reported to bind Endoglin directly (10). Endoglin modifies ligand-induced signaling in multiple ways. For example, expression of Endoglin can inhibit TGF-beta 1 signals but enhance BMP7 signals in the same myoblast cell line (11). In endothelial cells, Endoglin inhibits T beta RI/ALK5, but enhances ALK1-mediated activation (12). Deletion of mouse Endoglin causes lethal vascular and cardiovascular defects, and human Endoglin haploinsufficiency can a cause the vascular disorder, hereditary hemorrhagic telangiectasia type I (13, 14). These abnormalities confirm the essential function of Endoglin in differentiation of smooth muscle, angiogenesis, and neovascularization (2‑4, 12‑14). In preeclampsia of pregnancy, high levels of proteolytically generated soluble Endoglin and VEGF R1 (sFLT1), along with low placental growth factor (PlGF), are pathogenic due to antiangiogenic activity (15).

1. Gougos, A. and Letarte, M. (1990) J. Biol. Chem. 265:8361.
2. ten Dijke, P. et al. (2008) Angiogenesis 11:79.
3. Bernabeu, C. et al. (2007) J. Cell. Biochem. 102:1375.
4. Mancini, M.L. et al. (2007) Dev. Biol. 308:520.
5. Moody, J.L. et al. (2007) Stem Cells 25:2809.
6. Velasco, S. et al. (2008) J. Cell Sci. 121:913.
7. Perez-Gomez, E. et al. (2005) Oncogene 24:4450.
8. Cheifetz, S, et al. (1992) J. Biol. Chem. 267:19027.
9. Barbara, N.P. et al. (1999) J. Biol. Chem. 274:584.
10. Scharpfenecker, M. et al. (2007) J. Cell Sci. 120:964.
11. Scherner, O. et al. (2007) J. Biol. Chem. 282:13934.
12. Pece-Barbara, N. et al. (2005) J. Biol. Chem. 280:27800.
13. Arthur, H.M. et al. (2000) Dev. Biol. 217:42.
14. Lebrin, F. and C.L. Mummery (2008) Trends Cardiovasc. Med. 18:25.    
15. Venkatesha, S. et al. (2006) Nat. Med. 12:642.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Endoglin/CD105 Antibody (MAB10971)(6)

Publications using MAB10971

• SM Koura, M Salama, M El-Hussiny, MEA Khalil, A Lotfy, SA Hassan, SA Gad Elhak, MA Sobh Fluoxetine induces direct inhibitory effects on mesenchymal stem cell?derived osteoprogenitor cells independent of serotonin concentration Mol Med Rep, 2019;0(0):. 2019 [PMID: 30720108] (Flow Cytometry, Rat)
• Feasibility and Efficiency of Human Bone Marrow Stromal Cell Culture with Allogeneic Platelet Lysate-Supplementation for Cell Therapy against Stroke Stem Cells Int, 2016;2016(0):6104780. 2016 [PMID: 27840648] (Flow Cytometry, Human)
• Vaculik C, Schuster C, Bauer W, Iram N, Pfisterer K, Kramer G, Reinisch A, Strunk D, Elbe-Burger A Human dermis harbors distinct mesenchymal stromal cell subsets. J. Invest. Dermatol., 2012;132(3):563-74. 2012 [PMID: 22048731] (IHC, Human)
• Davis D, Zhang Y, Smith R, Cheng K, Terrovitis J, Malliaras K, Li T, White A, Makkar R, Marban E Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS ONE, 2009;4(9):e7195. 2009 [PMID: 19779618] (IHC, Mouse)
• Riekstina U, Muceniece R, Cakstina I, Muiznieks I, Ancans J Characterization of human skin-derived mesenchymal stem cell proliferation rate in different growth conditions. Cytotechnology, 2008;58(3):153-62. 2008 [PMID: 19219561] (Flow Cytometry, Human)
• Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernabeu C, Botella LM Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb. Haemost., 2007;97(2):254-62. 2007 [PMID: 17264955] (Flow Cytometry, Human)

FAQs for Endoglin/CD105 Antibody (MAB10971). (Showing 1 - 2 of 2 FAQs).

1. I wonder if you have a CD105 or CD34 antibody suitable for IHC that is specific for human and do not bind mouse?
   • We do not have any anti-human CD34 or CD105 antibodies that are confirmed to NOT detect the mouse protein. When we have tested an antibody and confirmed that it will not react with mouse samples, we will add Mu(-) to the datasheet, and unfortunately all of our CD105 and CD34 antibodies will either detect the mouse protein, or they have not been used in mouse samples before.
2. We are interested in CD105 antibodies that could react with dog, please let me know which products in your catalog you would recommend.
   • We do not currently carry any CD105 antibodies that have been validated for use in dog samples. However, if you are interested in testing any of our CD105 antibodies with dog samples you would be eligible for our Innovators Reward Program, in which you can get a discount voucher for the purchase price of the product. Please contact us at innovators@novusbio.com with any questions regarding this program.

Bioinformatics

• Gene Symbol: ENG
• Uniprot:
  • Q5T9B9()